DNA replication across blocking lesions occurs by translesion DNA synthesis (TLS), involving a multitude of mutagenic DNA polymerases that operate to protect the mammalian genome. Using a quantitative TLS assay, we identified three main classes of TLS in human cells: two rapid and error-free, and the third slow and error-prone. A single gene, REV3L, encoding the catalytic subunit of DNA polymerase f (polf), was found to have a pivotal role in TLS, being involved in TLS across all lesions examined, except for a TT cyclobutane dimer. Genetic epistasis siRNA analysis indicated that discrete two-polymerase combinations with polf dictate error-prone or error-free TLS across the same lesion. These results highlight the central role of polf in both error-prone and error-free TLS in mammalian cells, and show that bypass of a single lesion may involve at least three different DNA polymerases, operating in different two-polymerase combinations.
Introduction
Despite the existence of efficient DNA repair mechanisms, DNA replication encounters unrepaired lesions, which may lead to arrested progression of replication forks and the formation of replication gaps (Rupp and Howard-Flanders, 1968; Lehmann, 1972; Meneghini, 1976; Friedberg et al, 2006; Lehmann and Fuchs, 2006; Lopes et al, 2006; Mojas et al, 2007) . Translesion DNA synthesis (TLS) is a ubiquitous error-prone response to arrested replication forks and gaps, which is conserved from Escherichia coli to humans. TLS is mediated by specialized DNA polymerases that are characterized by low fidelity and an ability to replicate across certain types of damaged sites in template DNA. Such replication can be accurate with respect to the nucleotide composition of the damaged template, or inaccurate, leading to the generation of mutations (Livneh, 2001; Goodman, 2002; Prakash and Prakash, 2002; Lehmann et al, 2007) .
TLS in E. coli involves a single major DNA polymerase, DNA polymerase V, (Reuven et al, 1999; Tang et al, 1999) , functioning in error-prone TLS across a diversity of DNA lesions (Reuven et al, 1999; Tang et al, 1999 Tang et al, , 2000 MaorShoshani et al, 2003) . E. coli also contains DNA polymerases II and IV, which bypass lesions under specific situations (Napolitano et al, 2000; Jarosz et al, 2006) . In Saccharomyces cerevisiae, two genetically distinct TLS pathways have been defined by the DNA polymerases involved. A polZ (RAD30)-dependent pathway performs TLS across a TT CPD (thymine-thymine cyclobutane pyrimidine dimer) with high fidelity (Johnson et al, 1999b) , and a polz (REV3 and REV7)-dependent pathway functions in error-prone TLS across UV-induced lesions (Nelson et al, 1996a, b; Lawrence, 2002; Gibbs et al, 2005) , and other damages (Xie et al, 2003; Zhao et al, 2006) . A key regulatory element in TLS is PCNA, the monoubiquitination of which signals the switch from high-fidelity replication to TLS (Hoege et al, 2002; Stelter and Ulrich, 2003) .
The situation in mammalian cells is more complicated, due to the presence of many more low-fidelity DNA polymerases than in E. coli or S. cerevisiae: four specialized Y-family DNA polymerases (compared with two in E. coli and S. cerevisiae), and six additional low-fidelity polymerases that belong to other DNA polymerase families (Hubscher et al, 2000; Goodman, 2002) . As in yeast, the monoubiquitination of PCNA appears to have an important regulatory function (Kannouche et al, 2004; Watanabe et al, 2004; Bienko et al, 2005; Bi et al, 2006) . Moreover, both monoubiquitination of PCNA, and the efficiency and accuracy of TLS are regulated by the p53-inducible protein p21 (Avkin et al, 2006; Soria et al, 2006) through its interaction with PCNA (Avkin et al, 2006) . However, many mechanistic aspects of TLS are still unknown. In the present study, we used kinetics and genetic analysis of TLS based on gene knockout or knockdown, in conjunction with gapped plasmids carrying single site-specific lesions to decipher some of the operation principles of TLS in mammalian cells. Our results indicate that there exist at least three major pathways of TLS in mammalian cells, and that a single polymerase, DNA polymerase z (polz), has a pivotal and irreplaceable role in TLS across a wide variety of DNA lesions in mammalian cells. It functions in both errorfree and error-prone TLS, and cooperates with other DNA polymerases in two-polymerase mechanisms. These results highlight the crucial function polz has in TLS, and provide the first evidence for a two-polymerase mechanism in living mammalian cells.
Results

TLS exhibits distinct classes of kinetics and accuracy in human cells
In this study, we utilized a quantitative TLS assay system based on gapped plasmids carrying site-specific DNA lesions in the single-stranded region opposite to the gap (gap-lesion plasmid) (Avkin et al, 2002 (Avkin et al, , 2004 Adar and Livneh, 2006) (Supplementary Figure 1s) . Briefly, cultured cells were transfected with a plasmid mixture comprising a gap-lesion plasmid with a site-specific lesion opposite a gap and a kan R marker, a control gapped plasmid without a lesion (cm R ), and an intact carrier plasmid (amp R ). After allowing time for TLSdependent gap filling, plasmids were extracted from the cells using alkaline conditions, such that only fully repaired plasmids remain covalently closed, and those were used to transform an E. coli recA indicator strain, which is defective in TLS. The bacterial cells were plated in parallel on kan-LB plates to select for repaired gap-lesion plasmids, and on cm-LB plates to select for the control plasmid. The extent of TLS was determined from the ratio of kan R /cm R E. coli colonies. To determine the fidelity of TLS, plasmids were extracted from individual kan R colonies and subjected to DNA sequence analysis across the region corresponding to the gap. We demonstrated earlier that this assay system reflects TLS events occurring in the mammalian cell (Avkin et al, 2002) , is responsive to the cellular composition of DNA polymerases in a way similar to chromosomal TLS (Avkin et al, 2004; Hendel et al, 2008) , and subject to regulation by p53 and p21 through PCNA ubiquitination (Avkin et al, 2006) . The plasmids become chromatinized in the cells (data not shown), and may better reflect TLS events occurring at post-replication gaps, rather than replication forks (e.g. behind the fork; Niimi et al, 2008) .
Using the gapped plasmid assay system, we measured the time course of TLS across six diverse, site-specific lesions, to obtain a general view on the kinetics of TLS. The lesions included benzo[a]pyrene-guanine (BP-G; ( þ )-trans-BPDE-N 2 -G adduct), a major tobacco smoke-induced DNA lesion; cisplatin-GG (cisPt-GG), an intra-strand adduct formed in DNA by the cancer chemotherapy drug cisplatin; a furanyl AP (apurinic/apyrimidinic (abasic)) site, which is a synthetic analogue of the native AP site generated in DNA by spontaneous hydrolysis; 4-hydroxyequilenin-C (4-OHEN-C), an adduct formed in DNA by metabolites of equilin and equilenin, which are widely used in oestrogen replacement therapy; and TT CPD and thymine-thymine 6-4 photoproduct (TT 6-4 PP), the two main UV-induced DNA lesions. As can be seen in Figure 1 (and Supplementary Tables 1s-6s ), the six time course curves fell into three kinetically distinct groups. TLS across the TT CPD was very rapid, and highly efficient, reaching nearly 40% bypass after 1 h, and over 85% after 8 h (Figure 1; Supplementary Table 1s) . TLS across the BP-G and cisPt-GG adducts exhibited an initial lag of 1-2 h, after which it proceeded at a fast pace, reaching B40% bypass after two additional hours, and B60% at 8 h after the lag (Figure 1 ; Supplementary Tables 2s and 3s) . TLS across TT 6-4 PP, the AP site and 4-OHEN-C was slow and relatively inefficient, reaching 14-27% bypass after 24 h (Figure 1 ; Supplementary Tables 4s-6s ). These results are quite remarkable, given that the lesions that share similar kinetics are chemically very different, and have no obvious structural, conformational, or chemical commonalities.
The fidelity of TLS across each lesion was determined using DNA sequence analysis. As can be seen in Figure 2A -F (and Supplementary Tables 7s-12s), each lesion exhibited a unique mutational signature, consistent with previous results (Friedberg et al, 2006) , except for 4-OHEN-C, for which no previous mammalian in vivo mutational data existed. TT CPD, BP-G, and cisPt-GG were bypassed accurately in approximately 90% of the TLS events (error frequency of approximately 10%; Figure 2A -C; Supplementary Tables 7s-9s). In contrast, TLS across TT 6-4 PP and 4-OHEN-C was highly mutagenic with error frequencies in the range of 71-75% (Figure 2D and E; Supplementary Tables 10s and 11s). Most of the mutations occurred opposite the damaged template bases; however, for TT CPD, TT 6-4 PP, and 4-OHEN-C, a significant fraction of the mutations were semitargeted to the two nearest bases flanking the lesion (Figure 2A-F; Supplementary Tables 7s-12s ). The mutagenicity of TLS across an AP site cannot be defined in the absence of knowledge of the missing base. However, as spontaneous depurination is much faster than depyrimidination, most AP sites generated are at purines. Therefore, any insertion of a purine nucleotide opposite the AP site can be considered functionally mutagenic, providing a minimal estimate of its mutagenicity during TLS. Interestingly, the fidelity of bypass correlated with its speed and efficiency: The rapid and efficient TLS across TT-CPD, BP-G, and cisPt-GG was accurate, whereas the slow and inefficient TLS across TT 6-4 PP, 4-OHEN-C and an AP site was highly mutagenic (Figure 2G-I ).
Polf is involved in both error-free and error-prone TLS If the kinetically distinct branches of TLS represent distinct pathways, they should exhibit characteristic genetic requirements, particularly of TLS DNA polymerase genes. For the three lesions that were bypassed by rapid and accurate TLS, there is evidence for the involvement of specific DNA polymerases: polZ for TLS across TT CPD and cisPt-GG, and polk for TLS across BP-G. This is based on in vivo studies (Maher et al, 1976; Ogi et al, 2002; Bassett et al, 2004) , in vitro results with purified DNA polymerases (Johnson et al, 1999a; Masutani et al, 1999 Masutani et al, , 2000 Ohashi et al, 2000; Vaisman et al, 2000) , as well as studies from our lab using the gap-lesion plasmid assay utilized here (Avkin et al, 2004; Hendel et al, 2008) (and see below). As for the lesions in the slow and mutagenic branch of TLS, based on studies in S. cerevisiae (Haracska et al, 2001; Gibbs et al, 2005 ) and human cells (Gibbs et al, 1998) we suspected that their bypass involves polz. We therefore analysed TLS across these three lesions in Rev3L þ / þ and Rev3L À/À (the mouse homologue of the yeast REV3 gene, encoding the catalytic subunit of DNA polymerase z) mouse embryonic fibroblasts, using the gaplesion plasmid assay system. As controls, we examined TLS across the three lesions bypassed by the rapid and accurate branches of TLS. In addition, we examined TLS across an artificial lesion in the form of a chain of 12 methylenes inserted into the DNA backbone (M12; Adar and Livneh, 2006) . As can be seen in Figure 3A and Supplementary Table 13s , for all lesions except the TT CPD, TLS was significantly reduced in Rev3L À/À cells, compared with Rev3L þ / þ cells.
This reduction was 7.3-fold for the BP-G adduct, 3.5-fold for the cisPt-GG adduct, 2-fold for the AP site, 2.8-fold for the 4-OHEN-C lesion, 5.3-fold for the TT 6-4 PP, and 7.8-fold for the M12 lesion ( Figure 3A ; Supplementary Table 13s ). Thus, polz appears to be involved not only in TLS across lesions classified as being bypassed via the slow and mutagenic pathway but also across lesions bypassed by rapid and accurate TLS, except for TT CPD. The extent of TLS across several lesions in the mouse cells ( Figure 3 ) was quantitatively different from that obtained in the human cells ( Figure 1 ). This may stem from the difference in organisms and cell types, and the fact that the mice cells were p53 null, a situation under which TLS is deregulated (Avkin et al, 2006) . Therefore, to examine whether REV3L is similarly involved in TLS in the human cell line U2OS used in the kinetics analysis (which has a wild-type p53), we analysed TLS across several lesions in U2OS cells in which the expression of REV3L was knocked down using siRNA. As can be seen in Figure 3C , transfection of U2OS cells with REV3L siRNA caused a strong reduction in REV3L mRNA expression, whereas the control siRNA had essentially no effect. We then assayed TLS across four different lesions. As can be seen in Figure 3D and Supplementary Table 21s, when REV3L was knocked down, TLS across TT 6-4 PP, cisPt-GG, and BP-G was decreased compared with the control siRNA. In contrast, TLS across the TT CPD was similar. Thus, similar to the MEF, polz is involved in TLS in the human cell line U2OS across lesions classified as being bypassed via the slow and mutagenic pathway, as well as the rapid and accurate pathway, with the exception of TT CPD.
Residual TLS in the absence of polf in murine cells is more accurate
To determine the sequence changes at the lesion caused by the absence of Rev3L, DNA sequence was analysed in descendants of gap-lesion plasmids that were repaired in Rev3L-proficient or Rev3L-deficient cells. As shown in Figure 3B and Supplementary Table 14s, in Rev3L þ / þ MEF 62% of TLS events across BP-G were error-free, involving the incorporation of dCMP, consistent with previous results (Avkin et al, 2004) . In total, 37% of the TLS events across BP-G were mutagenic, involving insertion of mainly dAMP and dTMP opposite the lesion, although G was also misinserted (Supplementary Table 14s ). The major effect in Rev3L
MEF was, of course, the strong decrease in TLS, as shown in Figure 3A . DNA sequence analysis of plasmids that were repaired in the Rev3L À/À MEFs showed that a substantial fraction contained large deletions and insertions, indicative of the formation of DSB (27%; Supplementary Table 14s ). The absolute frequency of these events was similar in Rev3L À/À and Rev3L þ / þ MEFs, indicating that they were unrelated to polz. Interestingly, residual TLS was more accurate in the absence of Rev3L than in its presence, with only 5.9% mutagenic TLS events. Thus, residual TLS in the absence of Rev3L was very low, but 6.3-fold less mutagenic (P ¼ 0.0006; Figure 3B ; Supplementary Table 14s) . A similar effect was observed for cisPt-GG adduct ( Figure 3B ; Supplementary Table 15s): although 13% of the TLS events in Rev3L þ / þ cells were error-prone, that is, nucleotides other than CC were inserted opposite cisPt-GG lesions (Supplementary Table 15s ), remarkably, all 54 plasmids isolated from Rev3L À/À cells contained the correct sequence (CC) opposite cisPt-GG adducts ( Figure 3B ; Supplementary Table 15s ). This reflects a misinsertion frequency of o1.8% (o1/54 events), indicating that TLS across a cisPt-GG adduct is at least 7.2-fold less mutagenic in the absence of Rev3L (P ¼ 0.0062). Similar phenomena were observed for 4-OHEN-C ( Figure 3B ; Supplementary Figure 3B ; Supplementary Table 18s ) similar to the situation in the human cells (Figure 2A ; Supplementary Table 7s) . We also examined insertion specificity across an AP site Table 19s ; Avkin et al, 2002) . For the M12 lesion, which represents a severe type of damage, the most pronounced effect was an increase in large deletions of the lesion area in Rev3L À/À cells (89%) compared with Rev3L þ / þ cells (38%), indicative of DSB formation followed by NHEJ, possibly due to a difficulty to bypass the lesion (Supplementary Table 20s ). When the mutational spectra were examined in the human cell line U2OS under conditions in which expression of REV3L was knocked down, there was essentially no difference in the accuracy of TLS compared with the control cells (Table I ). This may be due to an inherently more accurate TLS in human cells compared with mouse cells, which remained essentially unchanged even when expression of REV3L was knocked down, and TLS inhibited. For example, TLS across BP-G is less accurate in mice cells compared with human cells (Avkin et al, 2004 ; Table I; Supplementary Table 14s ).
Polf cooperates with polj in error-free TLS across BP-G in human cells As described above, due to the known role of polk in TLS across BP-G, the strong dependence on REV3L of TLS across this lesion was unexpected. We therefore decided to further study TLS across this lesion. A possible explanation for these findings was that both polk and REV3L are involved, perhaps in a two-polymerase pathway (Johnson et al, 2000a) . To examine this possibility, we took a gene-knockdown epistasis analysis approach, and assayed TLS in U2OS cells in which the expression of POLK, REV3L, or both was knocked down. As can be seen in Figure 4C , the POLK, POLH, and REV3L siRNAs each specifically knocked down the expression of its target polymerase by approximately 80-90%. Figure 4A and Supplementary Table 22s present the results of TLS across BP-G under these conditions. Knocking down the expression of POLK caused a 2.3-fold decrease in TLS, indicating that at least 57% of the BP-G adducts required POLK for bypass. Knocking down the expression of REV3L caused a stronger 5.5-fold decrease in TLS, indicating that at least 82% of the BP-G adducts required REV3L for bypass. When the expression of both POLK and REV3L was knocked down, TLS was essentially identical to its value in cells where only REV3L was knocked down ( Figure 4A; Supplementary Table 22s ). To examine whether the combination of any two polymerases would drastically affect TLS across BP-G, we assayed cells in which both POLK and POLH were knocked down. TLS across BP-G in cells in which POLH was knocked down was marginally decreased, whereas when both POLH and POLK were knocked down, TLS was similar to that observed in POLKknocked-down cells, indicating that polZ does not have a major role in the extent of TLS across BP-G ( Figure 4A ; Supplementary Table 22s ). If at least 82% of the BP-G adducts The percentage of mutagenic TLS is the fraction of events other than insertion of C opposite BP-G, or CC opposite cisPt-GG out of the total number of TLS events. c P-value is given compared with the results obtained with cells transfected with control siRNA. Analysis was performed using the w 2 test. P-values that reached statistical significance are in bold face type. U2OS cells were transfected with the indicated siRNAs. After incubation of 72 h, the plasmid mixtures containing the gap-lesion plasmid GP-BP-G1 or GP-cisPt-GG (kan R ), along with the control gapped plasmid GP20 (cm R ) and the carrier plasmid were introduced into the cells. Following incubation of 8 h to allow TLS, the DNA was extracted and used to transform a recA E. coli indicator strain. GP-BP-G1 or GP-cisPt-GG (kan R ) descendents were extracted from kan R colonies and subjected to DNA sequence analysis. Deletions and insertions are taken as non-TLS events.
are bypassed by polz, at most 18% are bypassed by other polymerases, without the involvement of polz. However, polk is involved in bypass of 57% of the BP-G adducts. This means that at least 39% of the lesions are bypassed in a TLS pathway that involves the action of both polk and polz.
TLS became 3.1-fold less mutagenic (P ¼ 0.042) when POLH was knocked down ( Figure 4B ; Table I ), whereas when POLK was knocked down, there was a 1.9-fold decrease in mutagenic TLS, but it did not reach statistical significance (P ¼ 0.2; Table I ). However, the fraction of deletions and insertions Figure 4 Polk and polz operate in the same TLS pathway to bypass BP-G in human cells. (A) Relative TLS extent across BP-G in U2OS cells in which the expression of specific TLS DNA polymerases was knocked down. The experiments were performed as described in the legend of Figure 3D , and the detailed data are presented in Supplementary Table 22s . TLS extents were given as percentage relative to TLS assayed with control siRNA, which was 10.9 ± 1.1% (see Supplementary Table 22s ). (B) Relative mutagenic TLS across BP-G based on DNA sequence information of plasmids isolated from colonies obtained in the experiments described in (A). The detailed data are presented in Table I . Mutagenic TLS, namely the fraction of nucleotides other than C inserted opposite BP-G, was calculated out of all TLS events, and presented relative to the mutagenic TLS in cells transfected with control siRNA (which was 13.6%; see Table I increased from 14 to 25.9% (P ¼ 0.012; Table I ), and a similar increase was observed when POLH was knocked down (Table I) . Consistently, when both POLH and POLK were knocked down, the effect was similar to knocking down POLH alone, suggesting that polZ is responsible for the majority of error-prone TLS across BP-G (Table I) . Knocking down both POLK and REV3L decreased mutagenic TLS across BP-G by 3.9-fold ( Figure 4B ; Table I ; P ¼ 0.037).
Polf cooperates with polg and polj in error-free and error-prone TLS, respectively, across cisPt-GG in human cells The question arises whether lesions additional to BP-G are bypassed by the two-polymerase mechanism. We chose to address this question by analysing TLS across the adduct cisPt-GG using the siRNA-based epistasis approach. This lesion was chosen because there is evidence that polZ (Bassett et al, 2004) and REV3L (Wu et al, 2004; Zander and Bemark, 2004) are involved in its bypass; however, as these were experiments performed with different cells and under different conditions it was unknown whether the two operate in the same pathway.
Analysis of TLS across cisPt-GG in cells in which the expression of POLH was knocked down caused a 53% reduction in TLS, whereas knocking down of REV3L caused an 82% decrease ( Figure 5A ; Supplementary Table 23s) . A similar drastic reduction in TLS (80%) was observed when both POLH and REV3L were knocked down. Surprisingly, knocking down the expression of POLK, not known to be involved in TLS across cisPt-GG, caused a 34% decrease, and consistently, knocking down both POLK and POLH caused a 78% reduction in TLS, similar to the effect caused by knocking down REV3L alone ( Figure 5A ; Supplementary Table 23s) . Thus, at least 82% of the cisPt-GG lesions are bypassed by polz, and a similar fraction is bypassed by polZ and polk combined. Taken together with the other data, this suggests that TLS across cisPt-GG can occur by at least two reactions, each involving two polymerases: one involving polZ and polz, and the other involving polk and polz. DNA sequence analysis revealed that the mutagenic TLS decreased by 5.7-fold when POLK was knocked down (Table I) . When POLH was knocked down mutagenic TLS remained unchanged but the fraction of deletions/insertions increased 4.5-fold (Po0.001; Table I ). Knocking down both POLH and POLK caused both a decrease in mutagenic TLS and an increase in deletions/insertions ( Figure 5B ; Table I ). Taken together, these results suggest that polz cooperates with polZ to carry out error-free TLS, and with polk to carry out error-prone TLS across cisPt-GG.
POLK affects cell viability in response to cisplatin in human XPA cells in which the expression of POLH was knocked down
To examine whether the unexpected involvement of POLK in TLS across the cisPt-GG adduct is relevant to chromosomal TLS, we examined the viability of XPA cells treated with cisplatin. These cells are deficient in nucleotide excision repair, and therefore cell viability in response to cisplatin was expected to be more dependent on DNA damage tolerance mechanisms such as TLS. As can be seen in Figure 5C , cell viability was reduced by 40% in cisplatin-treated (1 mM) cells in which the expression of POLH was knocked down compared with cells transfected with a control siRNA, consistent with the known involvement of POLH in TLS across cisplatin-DNA adducts. Knocking down POLK alone had essentially no effect; however, when both POLH and POLK were knocked down, the viability of cisplatin-treated cells decreased by 70% (3.3-fold decrease; Figure 5C ). At a lower cisplatin concentration (0.5 mM) knocking down POLH or POLK alone had no effect on viability, but knocking down both caused a 48% decrease in cell viability ( Figure 5C ). Although this does not provide direct proof for the involvement of POLK in chromosomal TLS across cisplatin adducts, it is consistent with such a possibility, further strengthening the conclusion from our gap-lesion plasmid assay. The experiments were performed as described in the legend of Figure 4A , and the detailed data are presented in Supplementary  Table 23s . (B) Relative mutagenic TLS across cisPt-GG based on DNA sequence information of plasmids isolated from colonies obtained in the experiments described in (A). The detailed data are presented in Table I . Mutagenic TLS, namely the fraction of nucleotides other than CC inserted opposite cisPt-GG, was calculated out of all TLS events, and presented relative to the mutagenic TLS in cells transfected with control siRNA (which was 18.3%; see Table I ). (C) Cisplatin sensitivity of XPA cells in which the expression of POLH and POLK was knocked down. XP12RO cells were transfected with the indicated siRNAs, after which they were treated with 0.5 or 1 mM cisplatin. Results are given relative to the viability of cells transfected with control siRNA (77 and 55% for 0.5 and 1 mM cisplatin, respectively). Cell viability was measured using a luminescence-based assay for measuring ATP.
Discussion
A pivotal role for polf in both error-prone and error-free TLS in mammalian cells Our results suggest that TLS operates in three distinct pathways: a very fast and accurate pathway that involves polZ, a delayed, accurate and fast TLS pathway, which involves two polymerases, including polz, and a slow and highly mutagenic pathway, which involves polz (Figure 6 ). Out of the seven DNA lesions examined, only TT CPD was bypassed in the very fast and accurate TLS pathway (Figure 1) . It is well established that polZ is involved in TLS across TT CPD (Maher et al, 1976; Johnson et al, 1999a; Masutani et al, 1999) , including in our assay (Hendel et al, 2008) . The TT CPD was the only lesion analysed, the bypass of which did not require polz. In fact, it may not need any DNA polymerase except for polZ, given its superior catalytic properties and its relatively high fidelity when replicating across a TT CPD (Johnson et al, 2000b; Masutani et al, 2000; McCulloch et al, 2004) . These properties are manifested during replication of UVirradiated cells in culture, as indicated by their ability to divide in the presence of CPD (Spivak and Hanawalt, 1992) . Given the evolutionary importance of UV light, the pathway of fast and accurate bypass of TT CPD by polZ may represent a special case, which is unique for CPD.
Mammalian cells contain no less than 15 DNA polymerases, yet polz stands out as a key TLS polymerase involved in TLS across all lesions examined, except the TT CPD. Moreover, unlike in the S. cerevisiae paradigm, where polz appears to be involved only in error-prone TLS, in mammals it is involved in both error-free and error-prone TLS. Although this is somewhat surprising, because the apparent lack of backup to the function of polz introduces vulnerability into the TLS system, it may explain why polz is the only TLS polymerase that is essential in mice Gan et al, 2008) . One possibility for having a common enzyme in several pathways is regulation; however, this possibility remains to be explored.
Discrete two-polymerase combinations define error-free and error-prone TLS across BP-G and cisPt-GG TLS across two of the lesions studied, BP-G and cisPt-GG involved the action of at least three polymerases: polk, polZ, and polz. Taking into account the properties of the human polk and polZ, and the putative polz (based on the S. cerevisiae polz; Johnson et al, 2000a) , the most likely explanation is that these lesions are bypassed in a two-polymerase mechanism: In the first step, polk or polZ inserts a nucleotide opposite BP-G or cisPt-GG, and in the second step, polz performs the extension past each of the two lesions ( Figure 6 ). Error-prone TLS across BP-G involves primarily polZ, as indicated by the decreased mutagenicity of TLS when POLH expression was knocked down (Table I ). In the case of cisPt-GG, both polZ and polk are involved in its bypass, and knocking down both causes a reduction of TLS similar to that caused by knocking down polz. Interestingly, polZ and polz together carry out largely error-free TLS, whereas polk and polz lead to a largely error-prone outcome of TLS across cisPt-GG. The involvement of polk in TLS across cisPt-GG was unexpected, as purified recombinant polk was reported to be unable to bypass a cisPt-GG lesion (Ohashi et al, 2000; Gerlach et al, 2001) . The in vivo activity may be enabled by interaction with auxiliary proteins. Its relevance to chromosomal TLS is indicated by the decreased viability of cisplatin-treated XPA cells in which both POLK and POLH were knocked down, compared with cells in which only POLH was knocked down ( Figure 5C ). Our results support the two-polymerase model for TLS proposed by L Prakash and S Prakash (Johnson et al, 2000a) based on experiments with purified proteins. To the best of our knowledge, the data presented here provide the first evidence for a two-polymerase TLS mechanism in living mammalian cells.
The fact that BP-G requires two polymerases for bypass in mammalian cells is surprising, because purified polk completely bypasses BP-G (Zhang et al, 2000; Avkin et al, 2004) . Moreover, human purified polk was shown to be a general extender (Washington et al, 2002) , similar to the yeast polz. Thus, under our conditions, the extender capacity of polk is not sufficient to catalyse efficient TLS across BP-G, and polz is needed. The need for polz in TLS across cisPt-GG is similarly surprising. Human purified polZ was shown to bypass cisPt-GG (Vaisman et al, 2000) , yet polz is needed for efficient TLS across it. A possible explanation might be that although polZ is efficient and accurate in incorporating a nucleotide opposite the 3 0 G of the cisplatin-GG lesion, it is inhibited at the 5 0 G (Alt et al, 2007) . Figure 6 A model for three pathways of TLS in mammalian cells. TLS across a TT CPD is rapid and accurate, and occurs most likely by a single DNA polymerase, polZ (A). TLS across cisPt-GG and BP-G occurs by a two-polymerase TLS pathway, which is rapid and accurate but delayed, and involves a combination of polz with either polZ or polk (B). TLS across an AP site occurs by a slow and highly mutagenic TLS pathway, which involves polz, and most likely an additional DNA polymerase (C). See text for details.
Our results are consistent with previous reports demonstrating the involvement of polk in chromosomal mutation induced by BP in mouse (Ogi et al, 2002; Bi et al, 2005) and of polz in human cells (Li et al, 2002) . Similarly, sensitivity to and mutagenesis by cisplatin in human cells involves polZ and polz (Bassett et al, 2004; Wu et al, 2004) . It should be emphasized that the chromosomal studies assayed survival and mutagenesis, not TLS, and therefore accurate TLS, which accounts for most TLS events across BP-G and cisPt-GG, could not be scored. Moreover, any effects observed in assaying chromosomal mutagenesis may have been caused by a combination of effects on excision repair, recombination repair, and checkpoint activation.
Slow and mutagenic polf-dependent TLS across a wide variety of DNA lesions Three lesions, TT 6-4PP, 4-OHEN-C, and AP site were bypassed in a slow and highly mutagenic fashion (up to 80% errors). The inferior TLS across these lesions compared with TLS across TT CPD, BP-G, and cisPt-GG may be due to a combination of the severity of the former, namely the large deviation from the normal structure that they force on the DNA, and the lack of an appropriate specialized DNA polymerase. After all, the repertoire of the DNA lesions far exceeds the number of TLS DNA polymerases. At this point, we do not know yet whether any other polymerase is required in this pathway in addition to polz. TLS across the AP site does not require polZ (Avkin et al, 2002) or polk (unpublished data), but is aphidicolin-sensitive, consistent with the involvement of an additional polymerase, perhaps pold (Avkin et al, 2002) . The big diversity of lesions bypassed by this pathway, including the M12 insert, which represents an artificial and severe type of DNA damage, suggests that this TLS pathway functions as a general-specificity TLS pathway, in charge of dealing with a variety of DNA lesions, including novel ones. Its mutagenic nature indicates that lesions are bypassed at the cost of increased mutation, a price that is apparently not too high given the alternative of a stuck replication fork or persistent gap, which might be broken leading to DSB. The slow rate of this pathway may reflect not only the difficulty of the TLS machinery to deal with these types of lesions but also a negative regulation to enable an alternative mechanism to act. Such a mechanism may involve the Rad5-dependent damage avoidance or homologous recombination repair, which cannot be detected in our assay.
Conclusions
The results presented here suggest that TLS operates in mammalian cells in at least three distinct pathways, of which two are fast and accurate, and one slow and mutagenic. Surprisingly, polz is involved in both error-free and error-prone TLS, making it a key and bottleneck component of the TLS system in mammalian cells. Moreover, evidence is presented that discrete two-polymerase combinations with polz dictate error-prone or error-free TLS across the same lesion: polk and polz carry out error-free TLS of BP-G, but error-prone TLS of cisPt-GG, whereas polZ and polz carry out error-free TLS of cisPt-GG, but error-prone TLS of BP-G. To the best of our knowledge, this is the first report on the involvement of mammalian polz in error-free TLS, and the first evidence for a two-polymerase mechanism in mammalian cells.
Materials and methods
Construction of gapped DNA substrates
The construction of gap-lesion plasmids was described earlier (Reuven et al, 1999; Avkin et al, 2002 Avkin et al, , 2006 Maor-Shoshani et al, 2003; Adar and Livneh, 2006; Hendel et al, 2008) , and is further detailed in the Supplementary data, along with the DNA sequences in the vicinity of the lesions.
In vivo TLS assay
The TLS assay was described earlier (Avkin et al, 2004 (Avkin et al, , 2006 . Briefly, cells were co-transfected with a mixture containing 50 ng of a gapped-lesion plasmid (kan R ), 50 ng of a gapped plasmid without lesion (GP20-cm, cm R ), and 10 mg of the carrier plasmid pUC18, using jetPEI/DNA complexes (Polyplus-transfection, Illkirch, France). For kinetics experiments, cells were transfected by electroporation with the Nucleofector TM system (Amaxa GmbH, Köln, Germany), which enables fast delivery. A similar DNA mixture was used, except that it contained 4.9 mg of the carrier plasmid pUC18. The gap-filling kinetics of the normalizing plasmid itself (GP20) was examined by transfecting U2OS cells with a mixture of GP20 (kan R ) and a normalizing covalently closed plasmid pSA26 (cm R ) (Avkin et al, 2002) , and found to be completely filled in less than 30 min (data not shown). The efficiency of gap repair was calculated by dividing the number of transformants obtained from the gap-lesion plasmid (number of colonies on LB-kan plates) by the number of corresponding transformants obtained with the control gapped plasmid GP20-cm (number of colonies on LB-cm plates). Plasmids were extracted from kan R colonies, and the sequence opposite the lesion was determined by automated DNA sequencing analysis in the Biological Services Department at the Weizmann Institute. To obtain values of TLS from values of gap repair, the latter were multiplied by the percentage of TLS events out of the total events, as determined by the DNA sequence analysis.
Knocking down of DNA polymerase genes
The expression of specific DNA polymerase genes was knocked down in U2OS cells by transfection with specific siRNA pools (50 nM) in 6-cm plates. All siRNAs were from Dharmacon: POLK SMARTpool M-021038, REV3L SMARTpool M-006302, POLH SMARTpool M-006454, and siControl non-targeting pool D-001206-14. Transfection was carried out using 12 ml/plate HiPerFect (Qiagen). After 48 h in culture with siRNA, cells were split 1:3, and after additional 24 h the TLS assay was conducted as described above.
Measurement of viability of cisplatin-treated human cells
Human XP12RO (SV40-tranformed XPA) cells were reverse-transfected with on-target plus siRNA (Dharmacon) in a 96-well plate format, and after 24 h the medium was replaced with a fresh medium containing 0.5 or 1 mM cisplatin. Viability was measured 72 h later, using CellTiter-Glo luminescent cell viability assay, which measures ATP levels (Promega).
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
